The Project
The European Joint Action on Personalised Cancer Medicine (JA PCM) brings together 29 European countries and 151 partner organisations to advance personalised cancer care across Europe. The 4 year project (2025-2029) aims to create a sustainable cross-border network to foster innovation, good practice, equity, and collaboration in personalised cancer care. The project is co-funded by the European Commission and has an overall budget of €31.6 million.
Consortium
JA PCM brings together 151 organisations from 29 European countries, making it one of the most ambitious joint actions under the EU4Health Programme. The project is coordinated by Sciensano (Belgium).
Partners list
Synergies/Collaboration
The Joint Action on Personalised Cancer Medicine (JA PCM) is designed to build upon and collaborate with a wide range of existing, past, current, and future initiatives to maximize its impact and ensure sustainable outcomes.
The European Commission has launched multiple initiatives in the field of cancer care, it is therefore important to build on these initiatives, to create synergies and avoid duplication. The JA PCM therefore includes several strategies to implement synergies with other EU initiatives in the field of cancer. Synergies with the parallel European project SPARC (Support of Personalised Medicine Approaches in Cancer) a Coordination and Support Action (CSA) have been developed, alongside synergies with other EU initiatives.
By leveraging the strengths and outputs of these initiatives, JA PCM aims to create a cohesive and integrated approach to personalised cancer medicine across Europe.